Open Access

The prognostic value of muscle regional oxygen saturation index in severe community-acquired pneumonia: a prospective observational study

  • Laura Claverias1, 2Email authorView ORCID ID profile,
  • Michael Marí1,
  • Judith Marín-Corral1,
  • Mónica Magret1,
  • Sandra Trefler1, 2,
  • María Bodí1, 2,
  • Antonio García-España2,
  • Juan Carlos Yébenes5,
  • Sergi Pascual3, 4,
  • Joaquim Gea3, 4 and
  • Alejandro Rodríguez1, 2
Journal of Intensive Care20164:7

DOI: 10.1186/s40560-016-0129-4

Received: 28 August 2015

Accepted: 13 January 2016

Published: 19 January 2016



Community-acquired pneumonia (CAP) mortality exceeds 20 % in critical care patients despite appropriate antibiotic therapy. Regional tissue oxygen saturation index (rSO2) measured with near-infrared spectroscopy (NIRS) might facilitate early detection for patients at risk of serious complications. Our objectives were to determine the relationship between early determination of rSO2 and mortality and to compare discrimination power for mortality of rSO2 and other resuscitation variables in critically ill CAP patients.


This is a prospective observational study. Patients with CAP were enrolled within 6 h to intensive care admission. Demographics and clinical variables were recorded. rSO2 was determined using NIRS in brachioradialis muscle. All variables were determined at baseline and 24 h after admission.


Forty patients were enrolled. Fourteen patients (35 %) had a baseline rSO2 < 60 % and 7 of them died (50 %). Only 1 of 26 (3.8 %) patients with rSO2 ≥ 60 % died (p = 0.007). The area under ROC curve (AUROC) showed consistent mortality discrimination at baseline (0.84, p = 0.03) and at 24 h (0.86, p = 0.006) for rSO2 values. Cox regression analysis showed that “low” rSO2 at ICU admission (hazard ratio (HR) = 8.99; 95 % confidence interval (CI) 1.05–76.8; p = 0.045) and “low” rSO2 at 24 h (HR = 13.18; 95 % CI 1.52–113.6; p = 0.019) were variables independently associated with mortality. In contrast, other variables such as Acute Physiology and Chronic Health Evaluation (APACHE II) score (HR = 1.09; 95 % CI 0.99–1.19; p = 0.052) were not associated with mortality.


Our findings suggest that forearm skeletal muscle rSO2 differs in patients with severe CAP according to outcome and might be an early prognosis tool.


Community-acquired pneumonia Sepsis Septic shock Microcirculation Near-infrared spectroscopy


Community-acquired pneumonia (CAP) is an important cause of morbidity, mortality and increased health-care costs [13]. CAP is considered severe when admission to the intensive care unit (ICU) is needed due to respiratory distress or septic shock and occurs in about 9–16 % of hospitalized patients [4, 5]. In patients with severe CAP, mortality rates ranged from 20 to 50 % according to the presence of shock, the accuracy of process of care, need for mechanical ventilation and underlying diseases [19]. Prompt initiation of appropriate antibiotic therapy and adequate resuscitation are recommended as it potentially benefits patients’ prognosis [10, 11] However, the mortality rate in immunocompetent patients admitted to the ICU by CAP with appropriate antibiotic therapy exceeds 20 % [3] suggesting that antibiotics alone are not enough.

Microvascular alterations are recognized as a key characteristic contributing to organ dysfunction and death in patients with sepsis [1214]. Microvascular dysfunction leads to reduced oxygen delivery and extraction, causing heterogeneous and deficient tissue oxygenation, which is associated with adverse clinical outcome.

Global hemodynamic and metabolic parameters are used in current practice as resuscitation endpoints in severe sepsis and septic shock [11]. However, normalization of relevant variables such as mean arterial pressure (MAP), central venous pressure (CVP), cardiac output (CO) or serum lactate is not enough to define oxygenation status and aerobic metabolism in peripheral tissues [1521] Increasing evidence suggests that regional oxygen saturation index (rSO2) determined by near-infrared spectroscopy (NIRS) might allow early detection of patients at risk of serious complications and have prognostic implications [17, 18].

We hypothesized that brachioradialis muscle rSO2 could reflect the prognosis in patients with severe CAP.


Ethics, consent and permissions

The study was performed from January 2011 to December 2013 in a 30-bed medical-surgical ICU in a tertiary university hospital. It was a prospective single centre, observational clinical study. The investigation was conducted according to the principles outlined in the Declaration of Helsinki. The study protocol was approved by the Joan XXIII University Hospital Ethics Committee (MICRO2 20/2010), and informed consent was given by each patient or their next of kin.

Study population

Consecutive adult patients with severe CAP requiring admission to the ICU were enrolled. The diagnosis of CAP was based on (a) the detection of a new and persistent pulmonary infiltrate for which there is no other explanation and at least two of the following clinical criteria: (1) fever or hypothermia (temperature >38 or < 35.5 °C); (2) leucopenia or leukocytosis (white blood cells ≤4x109/L−1 or ≥12 x109/ L−1) or (3) purulent respiratory secretions and (b) acquisition of the infection outside a hospital, long-term care facility or nursing home [22]. Patients were admitted to the ICU if they presented at least one of following criteria: signs and symptoms of respiratory failure (respiratory rate >30/min, accessory musculature utilization, low SpO2 despite oxygen supplementation), needed mechanical ventilation, or presented with criteria of severe sepsis or septic shock. All patients admitted to the ICU were considered to present severe CAP. We decided to include only CAP patients in order to obtain a homogeneous population of patients to increase the internal validity of the study.

We excluded (a) patients <18 years old; (b) immunosuppression, defined as any primary immunodeficiency or immunodeficiency secondary to HIV infection, active malignancies, radiation treatment or use of cytotoxic drugs, or steroids drugs (daily doses >40 mg of prednisolone or equivalent for >2 weeks), immunological disease, solid organ transplant and haematological disease; (c) hospital-acquired pneumonia or health-care-associated pneumonia; (d) morbid obesity (body mass index >30 kg/m2); (e) clinical edema and (f) injuries in forearms.

Study protocol

Patients were enrolled at ICU admission. Information collected included demographic characteristics, Acute Physiology and Chronic Health Evaluation (APACHE II) score [23], Sequential Organ Failure Assessment (SOFA) score [24] and global hemodynamic variables as heart rate (HR), CVP, MAP and mixed venous oxygen saturation (SvO2) when possible. Serum lactate and base deficit were obtained as markers of resuscitation and were determined at baseline and 24 h after ICU admission. The patients were treated with fluid administration and vasopressor therapy as required, according to the local guidelines adapted from Surviving Sepsis Campaign guidelines [11]. Patients were monitored at ICU admission using a central venous pressure (CVP) or echocardiography depending on the attending physician’s decision. Resuscitation was guided using CVP or echocardiography-derived parameters, and if advanced hemodynamic monitoring was needed, a pulmonary artery catheter was inserted. Fluid resuscitation was administered by fluid bolus challenge with crystalloids and/or artificial colloids, targeting a CVP 8–12 mmHg or if the patient showed >20 % collapsibility of the inferior cava vein during inspiration in ventilated patients (>50 % collapsibility in patients in spontaneous ventilation). When fluid administration was not enough to improve the patient’s hemodynamic status, the vasopressor agent of choice was norepinephrine titrated to the 2 μg/kg/min maximum dose to maintain the MAP >65 mmHg. Shock was defined as the need for vasopressors for >4 h after fluid replacement [8]. In accordance with our local guidelines, all patients were treated with antibiotic combination therapy (ceftriaxone plus macrolide) for CAP. All patients were evaluated during the first 24 h after ICU admission. We recorded if, at the time of admission, patients met major criteria according to the American Thoracic Society (need of mechanical ventilation or shock) [25]. Treatment was administered by an independent physician team that was blinded for rSO2 values. Patients were followed up for outcome data until ICU discharge or ICU death.

Regional oxygen saturation index (rSO2) measurements

A probe somasensor was placed on the medial forearm (brachioradialis muscle) at a distance 5 cm distal to the elbow of each subject to obtain skeletal muscle rSO2 measurement as described elsewhere [17, 18]. Measurements were obtained using a commercially available NIRS spectrometry system INVOS 5100C oximeter (Somanetics Corporation, Troy. MI, USA), with a non-sterile and disposable skin surface probe. This system functions with two NIRS probes, one with 30-mm and the other with 40-mm spacing between NIR light send and receive optical fibre tips. The 30-mm signal is subtracted from the 40-mm signal, with the intention of subtracting the skin and subcutaneous fat layer artefact from the underlying skeletal muscle. For all patients, rSO2 was recorded at baseline and at 24 h. NIRS data was not used in patients’ management. According to our previous data [17, 18], we defined a threshold in <60 % as a “low rSO2”.

Primary and secondary outcomes

The main objective of this study was to determine the relationship between early brachioradialis rSO2 values and mortality. Secondary outcomes were to compare the discrimination power for ICU mortality of brachioradialis rSO2 with standard variables of resuscitation and to evaluate the patients’ evolution according to the variation of rSO2 in the first 24 h.

Statistical analysis

Discrete variables are expressed as counts (percentage) and continuous variables as means and standard deviations or medians within the 25th to 75th interquartile range (IQR). For demographic and clinical characteristics of the patients, differences between groups were assessed using the chi-square test and Fisher’s exact test for categorical variables and the Student t test, Mann-Whitney U test or Kruskal-Wallis test for continuous variables. Pearson’s correlation coefficient was used to assess the association between continuous variables. The concordance of the values obtained for different correlations was assessed using the intraclass correlation coefficient (ICC), based on the model of analysis of variance for repeated measures by the process reliability. Cumulative survival was assessed using Kaplan-Meier plot. Cox regression analysis was performed to determine which variables were independently associated with mortality. We included the variables that showed a significant association with mortality in the univariate analysis as covariables in the model: APACHE II score, rSO2 value, presence of shock and need for mechanical ventilation. The predictive values for skeletal rSO2 and the other variables of resuscitation were calculated using a receiver operator characteristic (ROC) curve, and the area under ROC curve (AUROC) was computed. The ROC graph was a plot of all the sensibility/specificity pairs resulting from continuously varying the decision threshold over the entire range of results observed. Data analysis was made using SPSS for Windows 13.0 (SPSS, Chicago, IL, USA). For all analyses, p < 0.05 was considered significant.


Forty patients with severe CAP were enrolled. Median APACHE II score and SOFA score were 17.0 (IQR = 12–21) and 4.0 (IQR = 3–5) points respectively, with an overall ICU mortality of 20 %. Additional demographics, baseline and 24 h hemodynamic and biochemical data with simultaneous measurements of skeletal muscle rSO2 are shown in Table 1.
Table 1

Clinical characteristics, hemodynamic variables and biochemical data with simultaneous measurements of skeletal muscle rSO2 of 40 patients included


Overall (n = 40)

Survivors (n = 32)

Non-survivors (n = 8)

Demographic data


 Age (years), mean (SD)

55.5 (15.9)

53 (16.4)

65 (9.8)*

 Male, n (%)

27 (67.5)

21 (65.6)

6 (75.0)

Severity of illness


 APACHE II score at day 1, median (IQR 25–75)

17 (12–21)

16 (12–20)

22 (18–34)**

 SOFA score at day 1, median (IQR 25–75)

4 (3–5)

4 (3–5)

4 (3–8)

 Major ATS criteria, median (IQR 25–75)

28 (70)

20 (62.5)

8 (100)**

 Invasive mechanical ventilation, n (%)

21 (52.5)

13 (40.6)

8 (100)***

 Severe sepsis, n (%)

18 (44.5)

17 (53.1)

1 (12.5)

 Septic shock, n (%)

22 (55.5)

15 (46.9)

7 (87.5)*

Mean comorbidities, n (%)


 Tobacco use

3 (8.6)

3 (10.7)


 Chronic obstructive pulmonary disease

12 (33.3)

10 (34.3)

2 (28.6)

 Cardiac disease

8 (20)

6 (18.7)

2 (28.6)

 Diabetes mellitus

7 (20)

5 (17.9)

2 (28.6)

 Severe liver disease

1 (2.9)


1 (14.3)

Hemodynamic data, median (IQR 25–75)


 Heart rate, b/min

105 (86–114)

105 (87–114)

105 (85–113)

 Heart rate at 24 h

90 (77–100)

92 (79–103)

85 (70–99)

 Mean arterial pressure, mmHg

79 (71–94)

78 (72–98)

80 (69–88)

 Mean arterial pressure at 24 h

79 (70–93)

76 (70–96)

79 (71–90)

 Central venous pressure, mmHg

11 (9–15)

11 (8–15)

11 (10–14)

 Central venous pressure at 24 h

13 (13–16)

11 (7–16)

14 (12–15)

 Mixed venous oxygen saturation, %a

76 (70–79)

76 (69–79)

74 (74)

 Mixed venous oxygen saturation at 24 ha

70 (68–83)

70 (68–80)

80 (70–91)

Biochemical data, mean (SD)


 Baseline serum lactate, mM/L

3.0 (3.1)

2.5 (1.6)

4.8 (6.1)

 Serum lactate at 24 h

2.0 (2.2)

1.4 (0.6)

3.9 (4.0)

 Baseline base deficit

−3.5 (5.2)

−3.6 (5.4)

−2.7 (4.3)

 Base deficit at 24 h

−2.3 (4.1)

−1.9 (4.1)

−3.4 (4.2)

 Baseline haemoglobin levels, mg %

11.9 (1.8)

12.1 (1.9)

11.2 (1.1)

 Haemoglobin levels at 24 h

10.6 (1.7)

10.6 (1.9)

10.4 (1.1)

 Baseline serum glucose, mg %

166 (74.7)

158 (75.3)

197 (66.8)

 Serum glucose at 24 h

152 (75.6)

144 (79.4)

177 (58.7)

 Baseline arterial pH

7.34 (0.1)

7.40 (0.1)

7.34 (0.3)

 Arterial pH at 24 h

7.36 (0.07)

7.30 (0.07)

7.32 (0.1)

 Baseline serum creatinine, mg %

1.40 (0.9)

1.38 (1.03)

1.41 (0.8)

 Serum creatinine at 24 h

1.1 (0.59)

0.9 (0.4)

1.5 (0.9)

rSO2 brachioradialsis


 Baseline rSO2, mean (SD)

62.9 (10.7)

68 (61–72)

46 (43–57)***

 rSO2 at 24 h, mean (SD)

65.4 (12.3)

69 (60–76)

52 (41–57)***

 Baseline rSO2 < 60, n (%)

14 (35)

7 (21.9)

7 (87.5)***

 rSO2 < 60 at 24 h, n (%)

6 (15.8)

4 (12.5)

7 (87.5)***

Therapy, mean (SD)


 Norepinephrine at baseline μg/kg/min

0.35 (0.26)

0.40 (0.14)

0.29 (0.36)

 Norepinephrine at 24 h, μg/kg/min

0.35 (0.29)

0.22 (0.28)

0.52 (0.23)*

 Fluid balance at 24 h, mL

1650 (1350)

1470 (800)

2300 (2500)

ICU length of stay


 Median IQR 25–75 %

18 (11–30)

18 (11–31)

24 (8–30)

SD standard deviation, IQR interquartile range, APACHE II Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, ATS American Thoracic Society, rSO 2 regional oxygen saturation index

For survivors vs. non-survivors comparison *p = 0.01; **p < 0.05; ***p < 0.001

aOnly 11 patients

Non-survivors had higher APACHE II score, greater need for invasive mechanical ventilation and higher frequency of septic shock compared to survivors. All non-survivors had major ATS criteria.

We found no significant differences in hemodynamic and biochemical data according to evolution. Brachioradialis rSO2 was the only variable associated with mortality at admission and at 24 h. Twenty-two patients (55 %) had shock at admission. Shock patients had lower rSO2 at baseline (59 % [SD 10.7] vs. 67 % [SD 8.9], p < 0.001) and at 24 h (61 % [SD 11.5] vs. 72 % [SD 10.6], p < 0.009) than patients without shock. However, we observed no significant correlation neither between MAP and rSO2 at baseline (r = 0.19, p = 0.90) and at 24 h (r = 0.07, p = 0.68) nor with rSO2 and norepinephrine doses at baseline (r = 0.11, p = 0.67) and at 24 h (r = −0.46, p = 0.06). In contrast, serum lactate at 24 h showed a weak but significant correlation with rSO2 at 24 h (r = 0.66, p = 0.001). In all cases, the concordance was poor and it was not significant. A central venous catheter for CVP measurement was inserted in 22 patients, the rest of them were monitored using echocardiography-derived parameters. SvO2 was available in only 11 (27, 5 %) patients. SvO2 values were 76 and 70 % at baseline and at 24 h, respectively. We observed no significant correlation between rSO2 and SvO2 at any time of the study (data not shown).

Patients with baseline “low rSO2” had a significantly higher ICU mortality rate than patients with rSO2 ≥ 60 % (Fig. 1). Fourteen patients (35 %) had a baseline skeletal muscle rSO2 < 60 %, and seven of them (50 %) died. In contrast, only one patient (3.8 %) with rSO2 ≥ 60 % died (p = 0.001). This represents more than sixfold increase in the risk of death (OR 6, 25; 95 % CI 1.0–39.4) despite similar levels of severity of illness and resuscitation variables (Table 2). We differentiate patients according to variation of the value of rSO2 from ICU admission to 24 h later. Three types of trends were observed: (1) a group of patients which showed no improvement or a decrease in rSO2 value (no responders); (2) other group which showed an improvement in rSO2 value to reach rSO2 of >60 % at 24 h (responders); and (3) a group of patients in which the rSO2 value improved but did not reach >60 % at 24 h (partially responders). We observed different outcomes according to initial rSO2 variation with a higher mortality rate in “no responders” (n = 3/7, 42.9 %) and “partially responders” (n = 3/7, 42.9 %) patients than “responder patients” (n = 1/26, 3.8 %, p < 0.005) with an OR = 18.7, 95 % CI 1.17–625.6 and a log rank = 5.99, p = 0.05 (Fig. 2). In addition, we performed a Cox regression analysis to determine if rSO2 < 60 % was associated with mortality. The regression analysis showed that “low” rSO2 at ICU admission (hazard ratio (HR) = 8.99; 95 % CI 1.05–76.8; p = 0.045) and “low” rSO2 at 24 h (HR = 13.18; 95 % CI 1.52–113.6; p = 0.019) were variables independently associated with mortality. In contrast, APACHE II score (HR = 1.09; 95 % CI 0.99–1.19; p = 0,052) was not associated with mortality (Table 3).
Fig. 1

Survival graph (Kaplan-Meier plot) for patients according baseline rSO2 cut-off values. ICU LOS intensive care unit length of stay (days), rSO 2 regional oxygen saturation index

Table 2

Levels of severity of illness and baseline resuscitation variables in 40 patients with severe community-acquired pneumonia according to basal brachioradialis muscle rSO2


rSO2 < 60 % (n = 14)

rSO2 ≥ 60 % (n = 26)

p value

APACHE II score , median (IQR 25–75)

18 (15–22)

15 (12–22)


SOFA score, median (IQR 25–75)

4,5 (3–5,5)

4 (3–5)


MAP (mmHg), median (IQR 25–75)

84 (69,7–93)

75 (71,7–94,7)


SL (mM/L), mean (SD)

4,2 (4,8)

2,3 (1,5)


BD, mean (SD)

−1,7 (6,7)

−4,4 (3,9)


Catecholamines (μg/kg/min), mean (SD)

0,39 (1,5)

0,32 (0,32)


Fluid balance at 24 h (mL), mean (SD)

2130 (2200)

1450 (759)


Need for MV, n (%)

8 (57)

13 (50)


ICU mortality rate, n (%)

7 (50)

1 (3,8)


APACHE II Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, MAP medium arterial pressure, SL serum lactate, BD base deficit, rSO 2 regional oxygen saturation index, MV mechanical ventilation, IQR interquartile range, SD standard deviation
Fig. 2

Survival graph (Kaplan-Meier plot) for patients according to variation (0–24 h) of rSO2 with treatment. No responders: which showed no improvement or a decrease in rSO2 value; Responders: patients which showed an improvement in rSO2 value to reach rSO2 of >60 % at 24 h and; Partially responders: patients in which the rSO2 value improved but did not reach >60 % at 24 h; ICU LOS intensive care unit length of stay (days), rSO 2 regional oxygen saturation index

Table 3

Results of cox regression analysis


Hazard ratio

95 % CI

p value

Presence of shock




Need of MV








“low” rSO2 (admission)




“low” rSO2 (24 h)




MV mechanical ventilation, APACHE II Acute Physiology and Chronic Health Evaluation, rSO 2 regional oxygen saturation, CI confidence interval

Finally, the discriminatory ability of each variable for ICU mortality was measured using the area under ROC curves (AUC). The AUC showed consistent mortality discrimination at baseline (0.84; 95 % CI 0.626–1.057, p = 0.004) and at 24 h (0.86; 95 % CI 0.646–1.075, p = 0.002) for rSO2 values, better than other resuscitation variables (Table 4).
Table 4

Area under ROC curve (AUROC). Discrimination for mortality of rSO2 and hemodynamic variables and APACHE II score



95 % CI

p value

rSO2 baseline




24 h




Lactate baseline




24 h




BD baseline




24 h




MAP baseline




24 h








CI confidence interval, rSO 2 regional oxygen saturation index, BD base deficit, MAP medium arterial pressure, APACHE II Acute Physiology and Chronic Health Evaluation


The main finding of our study is that in a population of patients with severe CAP, an early value of skeletal muscle rSO2 <60 % was associated with a worse prognosis despite similar severity of illness, representing near sixfold increase in the risk of death compared with patients with rSO2 ≥ 60 %. In addition, rSO2 variation (from admission to 24 h) allowed distinguishing three different types of responses to treatment which were associated with different evolution. To the best of our knowledge, our data is the first to report the relationship between rSO2 alterations and CAP prognosis with this NIRS device.

Despite advances in diagnosis and antimicrobial therapy, severe CAP remains an important cause of morbidity and mortality, especially in patients requiring ICU admission [16]. Unfortunately, it remains unknown whether specific clinical conditions or biomarkers can be used to identify patients with potential high risk of death.

Several risk factors that predict which patients will develop moderate to severe CAP have been identified in a small number of studies [13]. Our group [26] found that a prompt oxygenation assessment in the emergency department shortened the time taken to initiate antibiotic therapy and improved survival. Practice guidelines based on severity assessment tools, such as the ATS admission criteria or CURB-65 score, allow high-risk patients to be identified and given specific treatment. However, the prediction rule is derived from clinical data and laboratory parameters which are time-consuming, thereby limiting the clinical applications of predictive outcomes [27, 28]. Several biomarkers have been proposed to assess severity of illness and outcome. Inflammatory cytokines such as interleukin-6, procalcitonin, albumin and C-reactive protein levels have also shown to predict the severity of illness and 28-day mortality [29, 30]. However, most of these factors merely reflect individual coagulation and inflammation status and have no therapeutic potential in themselves. Therefore, identification of variables capable of not only predicting outcomes but also providing a potential therapeutic target would be more useful in clinical applications.

Microvascular alterations are frequently observed in patients with sepsis. In humans, several studies have shown that severity of the alterations in microvascular perfusion is associated with poor outcome [1214]. A crucial question is whether these microcirculatory alterations merely reflect the severity of the disease or contribute independently to mortality. Among the tools available for tissue microcirculation/oxygenation assessment, NIRS devices seem promising. It has been shown in different life-threatening conditions that muscle skeletal oxygen saturation might characterize tissue hypoperfusion and effectiveness of therapy in trauma [20] and septic shock [1719, 21]. However, the relationship between skeletal oxygen saturation with macrohemodynamics variables is not entirely clear. Small-sized trials showed that microvascular alterations were relatively independent of MAP, CO and vasopressor agent use [19, 31, 32]. In our study, no significant correlation was observed between the values of NIRS and classic hemodynamic variables. In contrast, other authors observed a significant relationship between CO and skeletal muscle oxygen saturation [20, 33]. In this way, our data cannot be compared with that available in the literature using other NIRS devices. Important technical differences should be considered before interpreting and comparing data based on NIRS technology. In the near-infrared range, oxyhaemoglobin (HbO2), deoxyhaeamoglobin (Hb) and oxidized cytochrome oxidase (CytOx) have characteristic absorption spectra. In order to derive concentration changes simultaneously for Hb, HbO2 and CytOx, values for absorption at four wavelengths of near infrared are often used. The calculation used to solve the modified Beer-Lambert equation at each of these wavelengths is known as an algorithm. Algorithms are different for each device and also vary depending on the presence of other chromophores and the precise values for the absorption coefficients chosen [3436]. Recent work has applied different published algorithms to the same data set and revealed striking differences in the calculated concentration changes [37, 38]. In addition, it is crucial to know the differential pathlength factor (DPF) when interpreting NIRS data. DPF is the distance travelled by each photon, and its value is derived from studies in healthy adults [39]; it may vary in other situations and is also wavelength-dependent. DPF may also change within the same subject over a period of time if the state of the tissue or tissue geometry alters [40]. Thus, probably, “normal” and critically “abnormal” tissue oxygenation values should be determined according to the critically ill patient population and the NIRS device used.

Besides differences regarding technical characteristics of each NIRS device, different values have been obtained when measuring rSO2 in different muscles. Our group found different values of rSO2 in brachioradialis and deltoid muscles of septic patients, although in each location “low” rSO2 values were associated with poor outcome [18]. Other groups have found these differences between muscles [41].

Although our patients in shock had lower values of rSO2 during the entire study period, we observed a non-significant relationship between MAP, vasopressor dose administered or SvO2 and rSO2. These findings may suggest that these variables do not affect rSO2 significantly. Classically, in septic shock, adequacy of perfusion for oxygen demand is assessed by serum lactate and base deficit levels [11, 15]. In the present study, serum lactate and base deficit levels were not associated with poor outcome. Skeletal muscle rSO2 may provide a more accurate reflection of oxygen delivery because it represents the balance between the oxygen supply to the capillaries directly beneath the sensor and oxygen consumption at that site independently of global hemodynamic state [17]. The rSO2 is indicative of oxygen extraction from haemoglobin and in comparison with arterial oxygen saturation, and possibly SvO2, it might provide a more accurate picture of hypoxia [17]. In fact, according to present data, the microcirculatory response to the treatment administered might be evaluated by the variation of rSO2. Patients with basal “low” rSO2 that respond appropriately to early treatment (first 24 h) and normalize the rSO2 (≥60 %) presented an ICU evolution significantly better than patients who despite improving rSO2 did not reach this cut-off.

The discriminatory ability for mortality was substantially higher for rSO2 than serum lactate and base deficit (except for 24 h). This suggests that skeletal muscle rSO2 can detect early poor tissue oxygenation that results in serum lactate or base deficit elevation during septic shock. Taking these into account, it is reasonable to think that rSO2 emerges as an early indicator of poor oxygenation with implications on prognosis. In addition, Cox regression analysis showed that “low” rSO2 value, both at ICU admission and at 24 h, was independently associated with mortality.

Our study had several limitations. First, the sample size was small in a single centre, which may account for some lack of statistical significance. The small patient population also prevented a subgroup analysis to further examine the differences in the effects of rSO2 on clinical outcomes according to some special clinical condition. However, clear differences in rSO2 values were observed between survivors and non-survivors. This suggests that rSO2 gives early evidence of patients with severe CAP who suffer oxygenation alterations with prognostic implications. Second, we not have been able to calculate the sample size to be included because there is no previous data with this population of patients and this NIRS device. However, we calculate the statistical power of our study which has been very high. Accepting a risk alpha of 0.05 in a bilateral contrast with 26 subjects in the first group (≥60 %) and 14 in the second (<60 %), the power of the contrast of hypotheses is 94 % to detect as a statistically significant difference that exists between 3, 5 % in the first group and 50 % in the second for mortality.

Third, NIRS does not directly measure microcirculatory flow. However, many studies [42, 43] have observed that NIRS values correlated well with global and specific organ perfusion parameters. In addition, NIRS signal is limited to vessels that have a diameter <1 mm (arterioles, capillaries and venules) and may be a useful tool for non-invasive monitoring of microcirculation in septic patients [13]. Fourth, we evaluated ICU mortality and not longer-term mortality, but the latter may also be influenced by other factors that are more related to the underlying disease and comorbidities. Fifth, we only included patients with CAP for which our data cannot be translated to other populations of patients with sepsis. Finally, we did not carry out a vascular occlusion test (VOT). VOT might to improve and expand the predictive ability of rSO2 in several scenarios [19, 44, 45]. However, our findings showed a high discriminatory power for absolute rSO2 values in accordance with our previous findings [17].


Our findings suggest that forearm skeletal muscle rSO2 determined at an early stage of severe community-acquired pneumonia is likely to be associated with outcome. Future studies are required to further substantiate our findings and to confirm the potential benefits of assessing skeletal muscle rSO2 on severe CAP.



We thank J. Francisco Avilés MD, PhD, for his statistical assessment and Phil Hoddy for the revision of English.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Joan XXIII University Hospital, Critical Care Department, IISPV/URV
Research Unit, Joan XXIII University Hospital, IISPV/URV
CIBER de enfermedades respiratorias (CIBERES), ISC III
Parc de Salut Mar, IMIM, Pneumology Department, CEXS, UPF
Critical Care Department, Mataró Hospital


  1. Khawaja A, Sarwar Zubairi AB, Durrani FK, Zafar A. Etiology and outcome of severe community-acquired pneumonia in immunocompetent adults. BMC Infect Dis. 2013;13:94–9.PubMedPubMed CentralView ArticleGoogle Scholar
  2. Ishiguro T, Takayanagi N, Yamaguchi S, Yamakawa H, Nakamoto K, Takaku Y, et al. Etiology and factor contributing to severity and mortality of community-acquired pneumonia. Intern Med. 2013;52:317–24.PubMedView ArticleGoogle Scholar
  3. Rodriguez A, Lisboa T, Blot S, Martin-Loeches I, Solé-Violan J, De Mendoza D, et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotic are not enough. Intensive Care Med. 2009;35:430–8.PubMedView ArticleGoogle Scholar
  4. Bodí M, Rodríguez A, Solé-Violán J, Gilavert MC, Garnacho J, Blanquer J, et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005;41:1709–16.PubMedView ArticleGoogle Scholar
  5. Rello J, Rodríguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J. 2006;27:1210–6.PubMedView ArticleGoogle Scholar
  6. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the Ward and the ICU. Chest. 2008;133:610–7.PubMedView ArticleGoogle Scholar
  7. Lisboa T, Blot S, Waterer GW, Canalis E, de Mendoza D, Rodriguez A, et al. Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest. 2009;135:165–72.
  8. Rodríguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Solé-Violán J, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007;35:1493–8.PubMedView ArticleGoogle Scholar
  9. Shorr AF, Bodi M, Rodríguez A, Solé-Violán J, Garnacho-Montero J, Rello J, et al. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest. 2006;130:93–100.PubMedView ArticleGoogle Scholar
  10. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotic and atypical presentation in community-acquired pneumonia. Chest. 2006;130:11–5.PubMedView ArticleGoogle Scholar
  11. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228.PubMedView ArticleGoogle Scholar
  12. Ellis CG, Jagger J, Sharpe M. The microcirculation as a functional system. Crit Care. 2005;9 suppl 4:S3–8.PubMedPubMed CentralView ArticleGoogle Scholar
  13. Ince C. The microcirculation is the motor of sepsis. Crit Care. 2005;9 suppl 4:S13–9.PubMedPubMed CentralView ArticleGoogle Scholar
  14. De Backer D, Donadello K, Sakr Y, Ospina-Tascon G, Salgado D, Scolletta S, et al. Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med. 2013;41:791–9.PubMedView ArticleGoogle Scholar
  15. Suistomaa M, Uusaro A, Parviainen I, Ruokonen E. Resolution and outcome of acute circulatory failure does not correlate with hemodynamics. Crit Care. 2003;7:R52.PubMedPubMed CentralView ArticleGoogle Scholar
  16. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med. 1995;333:1025–32.PubMedView ArticleGoogle Scholar
  17. Rodríguez A, Lisboa T, Martín-Loeches I, Díaz E, Trefler S, Restrepo MI, et al. Mortality and regional oxygen saturation index in septic shock patients: a pilot study. J Trauma. 2011;70:1145–52.PubMedView ArticleGoogle Scholar
  18. Rodríguez A, Claverias L, Marín J, Magret M, Rosich S, Bodí M, et al. Regional oxygen saturation index (rSO2) in brachioradialis and deltoid muscle. Correlation and prognosis in patients with respiratory sepsis. Med Intensiva. 2015;39:68–75.PubMedView ArticleGoogle Scholar
  19. Creteur J, Carollo T, Soldati G, Buchele G, De Backer D, Vincent JL. The prognostic value of muscle StO2 in septic patients. Intensive Care Med. 2007;33:1549–56.PubMedView ArticleGoogle Scholar
  20. Ikossi DG, Knudson MM, Morabito DJ, Cohen MJ, Wan JJ, Khaw L, et al. Continuous muscle tissue oxigenation in critically injured patients. A prospective observational study. J Trauma. 2006;61:780–90.PubMedView ArticleGoogle Scholar
  21. Mesquida J, Espinal C, Gruartmoner G, Masip J, Sabatier C, Baigorri F, et al. Prognostic implications of tissue oxygen saturation in human septic shock. Intensive Care Med. 2012;38:592–7.PubMedView ArticleGoogle Scholar
  22. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax. 2009;64(3):iii 1–15.Google Scholar
  23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.PubMedView ArticleGoogle Scholar
  24. Metnitz PG, Moreno RP, Almeida E, Jordan B, Bauer P, Campos RA, et al. SAPS 3—from evaluation of the patient to evaluation of the intensive care unit. Part 1: objectives, methods and cohort description. Intensive Care Med. 2005;31:1336–44.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Mandell LA, Wunderick RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of the community-acquired pneumonia in adults. CID. 2007;44:27–72.View ArticleGoogle Scholar
  26. Blot SI, Rodríguez A, Solé-Violán J, Blanquer J, Almirall J, Rello J, et al. Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med. 2007;35:2509–14.PubMedView ArticleGoogle Scholar
  27. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.PubMedPubMed CentralView ArticleGoogle Scholar
  28. Leroy O, Mikolajczyk D, Devos P, Chiche A, Grunderbeeck NV, Boussekey N, et al. Validation of a prediction rule for prognosis of severe community-acquired pneumonia. Open Respir Med J. 2008;2:67–71.PubMedPubMed CentralView ArticleGoogle Scholar
  29. Antunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 2002;20:990–5.PubMedView ArticleGoogle Scholar
  30. Bauer TT, Montón C, Torres A, Cabello H, Fillela X, Maldonado A, et al. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax. 2000;55:46–52.PubMedPubMed CentralView ArticleGoogle Scholar
  31. Baterman RM, Walley KR. Microvascular resuscitation as a therapeutic goal in severe sepsis. Crit Care. 2005;Suppl 4:S27–32.View ArticleGoogle Scholar
  32. van Beest PA, Vos JJ, Poterman M, Kalmar AF, Scheeren TWL. Tissue oxygenation as target for goal-directed therapy in high-risk surgery: a pilot study. BMC Anesthesiol. 2014;14:122.PubMedPubMed CentralView ArticleGoogle Scholar
  33. Bezemer R, Karemaker JM, Klijn E, Martin D, Mitchell K, Grocott M, et al. Simultaneous multi-depth assessment of tissue oxygen saturation in thenar and forearm using near-infrared spectroscopy during a simple cardiovascular challenge. Crit Care. 2009;13 Suppl 5:S5.PubMedPubMed CentralView ArticleGoogle Scholar
  34. Hazeki O, Tamura M. Near-infrared quadruple wavelength spectrophotometry of the rat head. Adv Exp Med Biol. 1989;248:63–9.PubMedView ArticleGoogle Scholar
  35. Piantadosi CA. Absorption spectroscopy for assessment of mitochondrial function in vivo. Methods Toxicol. 1993;2:107–26.Google Scholar
  36. Wickramasinghe Y, Thorniley M, Rolfe P, Houston R, Livera LN, Faris F. Developments of algorithms for non-invasive neonatal cerebral monitoring using NIRS. Proc 12th Ann Int Conf IEEE Eng. Biol Soc. 1990;49:762–6.Google Scholar
  37. Owen-Reece H, Smith M, Elwell CE, Goldstone JC. Near infrared spectroscopy. Br J Anaesth. 1999;82:418–26.PubMedView ArticleGoogle Scholar
  38. Matcher SJ, Elwell CE, Cooper CE, Cope M, Delpy DT. Performance comparison of several published tissue near infrared spectroscopy algorithms. Anal Biochem. 1995;227:54–68.PubMedView ArticleGoogle Scholar
  39. Duncan A, Meek JH, Clemence M, Elwell CE, Tyszczuk L, Cope M, et al. Optical pathlength measurements on adult head, calf and forearm and the head of the newborn infant using phase resolved optical spectroscopy. Phys Med Biol. 1995;40:295–304.PubMedView ArticleGoogle Scholar
  40. Deply DT, Cope M, van der Zee P, Arridge SR, Wray S, Wyatt JS. Estimation of optical path length through tissue from direct time of flight measurement. Phys Med Biol. 1988;33:1433–42.View ArticleGoogle Scholar
  41. Gómez H, Mesquida J, Simon P, Kim HK, Puyana JC, Ince C et al. Characterization of tissue oxygen saturation and the vascular occlusion test: influence of measurements sites, probe sizes and deflation thresholds. Crit Care. 2009, (doi:10.1186/cc8001)
  42. Nahum E, Skippen PW, Gagnon RE, Macnab AJ, Skarsgard ED. Correlation of near-infrared spectroscopy with perfusion parameters at the hepatic and systemic levels in an endotoxemic shock model. Med Sci Monit. 2006;12:BR313–7.PubMedGoogle Scholar
  43. Cohn SM, Varela JE, Giannotti G, Dolich MO, Brown M, Feinstein A, et al. Splanchnic perfusion evaluation during hemorrhage and resuscitation with gastric near-infrared spectroscopy. J Trauma. 2001;50:629–35.PubMedView ArticleGoogle Scholar
  44. Gómez H, Torres A, Polanco P, Kim HK, Zenker S, Puyana JC, et al. Use of non-invasive NIRS during a vascular occlusion test to assess dynamic tissue oxygen saturation response. Intensive Care Med. 2008;34:1600–7.PubMedView ArticleGoogle Scholar
  45. Payen D, Luengo C, Heyer L, Resche-Rigon M, Kerever S, Damoisel C, et al. Is thenar tissue hemoglobin oxygen saturation in septic shock related to macrohemodynamic variables and outcome? Crit Care. 2009;13 Suppl 5:S6.PubMedPubMed CentralView ArticleGoogle Scholar


© Claverias et al. 2016